Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT 1812 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms SHINE
  • Sponsors Cognition Therapeutics

    • Most Recent Events

    • 10 Oct 2019 According to a Cognition Therapeutics media release, this study is supported by grants from the organizations such as the Alzheimer's Drug Discovery Foundation (ADDF).
    • 29 Mar 2019 Planned number of patients changed from 160 to 120.
    • 29 Mar 2019 Planned End Date changed from 31 Dec 2019 to 31 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top